Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases Review

Tan, Aaron C, Boggs, Drexell H, Lee, Eudocia Q et al. (2022). Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases . Frontiers in Oncology, 11 10.3389/fonc.2021.780379

Open Access International Collaboration

cited authors

  • Tan, Aaron C; Boggs, Drexell H; Lee, Eudocia Q; Kim, Michelle M; Mehta, Minesh P; Khasraw, Mustafa

sustainable development goals

authors

publication date

  • January 3, 2022

published in

keywords

  • 1ST-LINE TREATMENT
  • CELL LUNG-CANCER
  • CNS metastases
  • DACOMITINIB
  • ENTRECTINIB
  • INTEGRATED ANALYSIS
  • LURBINECTEDIN PM01183
  • Life Sciences & Biomedicine
  • MULTICENTER
  • OPEN-LABEL
  • Oncology
  • SACITUZUMAB GOVITECAN
  • SINGLE-ARM
  • Science & Technology
  • brain metastases
  • intracranial efficacy
  • novel therapeutic agents
  • trial eligibility

Digital Object Identifier (DOI)

volume

  • 11